在患有曼诺斯结合性莱克 (MBL) 缺乏症患者的类固醇耐药密码性组织性肺炎 (COP) 中
Ilias E Dimeas1,2,3, Sotirios I Sinis3, Paraskevi Kirgou3
1School of Medicine University College Dublin Dublin 4 Ireland.
Respirology case reports
|February 2, 2026
概括
一名患有复发性呼吸衰竭的男子,最初被诊断为有组织性肺炎,经历了持续的症状. 鉴定出曼诺结合性莱克缺乏症,这可能会影响他的炎症反应和疾病进程.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 病理生理学 病理生理学
背景情况:
- 一名67岁的男性出现了复发性呼吸衰竭,发烧和双边透.
- 首次用甲基普雷迪尼索隆治疗疑似类似的发作后,出现了复发.
研究的目的:
- 为了调查复发性呼吸衰竭和类固醇耐药症状的根本原因.
- 提出一种病理生理学假设,用于患者的反抗性疾病过程.
主要方法:
- 临床病例介绍和诊断工作.
- 传染病工作 (血清,呼吸道样本) 和广泛的抗体面板.
- 胸部成像,支气管支气管洗分析和对类固醇反应的评估.
- 针对曼诺结合性莱克 (MBL) 缺乏症的遗传检测.
主要成果:
- 传染病和自身免疫检查结果为负.
- 胸部成像显示出迁移的不透明性;洗显示出混合细胞模式.
- 患者表现出类固醇反应,但在逐渐减少时经常出现恶化.
- 偶尔发现了曼诺结合性莱克缺乏症.
结论:
- 临床表现和诊断发现支持了对密码性组织性肺炎的临时诊断.
- 曼诺斯结合性莱克缺乏被假设阻碍了细胞亡的清除和调节炎症,有助于耐火性疾病的过程.
- 这种缺陷可能会影响炎症性肺病的发展轨迹,类似于其在COPD和移植后支气管炎 obliterans中所观察到的作用.
相关概念视频
00:59COP Coated Vesicles
18.2K
Membrane-enclosed structures called vesicles transport proteins and lipids across the cell. The vesicles derive their cargo from the plasma membrane, Golgi, ER, or endosome. Coated vesicles are spherical, protein-coated carriers with a 50–100 nm diameter that mediate bidirectional transport between the ER and the Golgi. The distribution of proteins between the ER and Golgi complex is dynamic and is maintained by different coated vesicles. Their formation is driven by the assembly of...
18.2K
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
325
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
325
01:30Pneumonia I: Introduction
892
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
892
01:29Pneumonia II: Pathophysiology
2.9K
The pathophysiology of pneumonia involves the following steps:
2.9K
02:18The Equilibrium Binding Constant and Binding Strength
15.1K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.1K
01:28Pneumonia IV: Management
815
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
815